The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, executed a transaction involving the sale of 1,000 shares of ResMed common stock at a price of $230.36 per share on March 10, 2025. This transaction was conducted under a pre-established Rule 10b5-1 plan, which provides certain legal protections for insider trading. The sale leaves Sandercock with a beneficial ownership of 90,864 shares, highlighting a strategic move within the company’s executive management.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, specializing in the development and manufacturing of products and solutions designed for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company focuses on improving patient outcomes and enhancing the quality of life for individuals with sleep and respiratory disorders.
YTD Price Performance: -0.68%
Average Trading Volume: 1,062,192
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$55.39B
Learn more about RMD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com